Happy Friday!
October is going by quickly, but if you need something else to help pass the time, why not give our podcast a listen? The two newest episodes of, “Wait, How Do You Spell That,” feature a conversation with a comic book artist working in the rare disease space and also a discussion about changing treatment protocols to better help rare patients in emergency medicine. You can find our podcast at PatientWorthy.com or by searching for “Wait, How Do You Spell That” on your favorite podcast app or service.
In this week’s Editor’s Choice, we have details about a new inhalant that is a potential treatment for cystic fibrosis. We also have information about a new study examining an investigative therapy for uvetic glaucoma. And finally, a new COVID-19 treatment is entering a phase 3 trial and we’ve got the details. We hope you have a great weekend!
New Inhalant Is a Potential Treatment for Cystic Fibrosis
The study showed positive results, with healthy volunteers seeing a significant decrease in the expression of epithelial sodium channel.
Positive Results for a Uveitic Glaucoma Investigative Therapy
Researchers found that the high dosage of the therapy produced better outcomes for patients on many measures.
New COVID-19 Treatment Enters Phase 3 Trial
This trial will evaluate Grifols’ anti-SARS-CoV-2 hyperimmune globulin, which provides a consistent and high concentration of neutralizing antibodies.
